CSMD1基因rs1613815基因型与肝细胞肝癌临床病理特征的关系

Objective To investigate the relationship between rs1613815 genotypes in CSMD1 gene with clinicopathological parameters of hepatocellular carcinoma (HCC) patients.Methods From Jan.to Jul. in 2009,146 pathologically confirmed HCC patients were enrolled from Department of Liver Surgery,Zhongshan Hospital,Fudan University.We collected the clinical and pathological data.The polymorphism of CSMD1 gene (rs1613815) was detected by USA Sequenom MassARRAY.According to the results of our previous pre-experiment,the relationship between different genotypes of rs1613815 and clinicopathological parameters of those HCC patients was analyzed retrospectively.Kaplan-Meier method and Cox regression model were used to estimate clinical outcomes.Results In the 146 cases of HCC,we found 33 cases carrying AA genotype,49 carrying AC genotype and 64 carrying CC genotype in rs1613815.In mid-advanced HCC patients,the incidence rate of tumor thrombi (including macroscopic and microscopic thrombi) in those patients carrying AC/CC genotype was apparently higher than those carrying AA genotype (70.6%vs.36.4%),and the difference was statistically significant (P=0.039).Meanwhile,the ratio of carring AC/CC genotype patients in T2-4 N0M0 was also significantly higher than those carrying AA genotype (59.8%vs.31.2%,P=0.004).No significant difference was found between AC/CC and AA genotype in age,gender,HbsAg,tumor size and number,serum alpha-fetoprotein(AFP) level and other clinicopathological parameters (P>0.05).In patients with tumor size ≥5 cm,the AA group had a significantly higher overall survival rate or recurrence-free survival rate than the AC/CC group (the P value was 0.023 and 0.005,respectively).Conclusions CSMD1 rs1613815 polymorphisms were positively correlated with tumor thrombi status and advanced TNM-stage of HCC,which indicated that it had a high potential of metastasis and poor prognosis.